Biochemical Engineering Special Interest Group
biological engineering professionals
17 March 2016

GSK adds Miltenyi Biotec to its oncology shopping CAR-T

GlaxoSmithKline ($GSK) and Miltenyi Biotec have signed an R&D cell and gene therapy pact that will see the British Big Pharma delve deeper into the brave new world of CAR-T-based oncology treatments. This brave new world will not however feature its leader, Andrew Witty, who announced his retirement today. Financial details between GSK and the German biotech have not been disclosed, but the companies said the collaboration will bring together GSK's experience in developing cell and gene therapy-based treatments with Miltenyi Biotec's platform in cell processing and related technologies in cell therapy. Source: Fierce Biotech 17/3/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).